Statements (53)
| Predicate | Object |
|---|---|
| gptkbp:instance_of |
gptkb:drug
|
| gptkbp:bfsLayer |
5
|
| gptkbp:bfsParent |
gptkb:Rinvoq
|
| gptkbp:activities |
Janus kinase inhibitor
|
| gptkbp:approves |
gptkb:2021
gptkb:FDA |
| gptkbp:brand |
gptkb:Rinvoq
|
| gptkbp:clinical_trial |
Phase 3
|
| gptkbp:contraindication |
active infections
hypersensitivity to the drug history of thrombosis |
| gptkbp:defines |
gptkb:ABBV-181
gptkb:upadacitinib_acetate |
| gptkbp:developed_by |
gptkb:Abb_Vie
|
| gptkbp:dosage_form |
15 mg once daily
30 mg once daily |
| gptkbp:excretion |
urine
feces |
| gptkbp:formulation |
tablets
|
| https://www.w3.org/2000/01/rdf-schema#label |
upadacitinib
|
| gptkbp:indication |
moderate to severe rheumatoid arthritis
moderate to severe ulcerative colitis moderate to severe atopic dermatitis |
| gptkbp:ingredients |
C17 H19 N5 O2
|
| gptkbp:interacts_with |
immunosuppressants
live vaccines strong CY P3 A4 inducers |
| gptkbp:is_atype_of |
L04 A A43
|
| gptkbp:is_monitored_by |
liver function tests
complete blood count lipid levels |
| gptkbp:is_used_for |
gptkb:ulcerative_colitis
gptkb:rheumatoid_arthritis atopic dermatitis |
| gptkbp:manager |
oral
|
| gptkbp:marketed_as |
gptkb:legislation
gptkb:Australia gptkb:United_States gptkb:Native_American_tribe |
| gptkbp:pharmacokinetics |
bioavailability 85%
metabolized by CY P3 A4 half-life 9-14 hours |
| gptkbp:population |
adults
children over 12 years |
| gptkbp:side_effect |
fatigue
headache nausea increased liver enzymes upper respiratory tract infections |
| gptkbp:status |
ongoing studies
post-marketing surveillance |
| gptkbp:type_of |
1252024-47-8
|
| gptkbp:weight |
317.36 g/mol
|